Resources

Cold chain maintenance workshop report: PATH, along with JSI, Village Reach, and CHAI, supported a workshop for over 50 cold chain technicians from six countries to gather and share best practices, engage in peer-to-peer learning, and explore ways to use data for improved cold chain maintenance and decision-making. The workshop report and results from a six-month follow-up survey can be found below.

This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on around the world.This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.To share any updates or corrections to the snapshot, please contact rsvsnapshot@path.org.

This spreadsheet provides publicly available information on clinical trials of respiratory syncytial virus (RSV) candidate vaccines and monoclonal antibodies intended for prevention.Sources of information for these trials are clinicaltrials.gov; who.int/clinical-trials-registry-platform; clinicaltrialsregister.eu; and anzctr.org.au, which includes clinical trial registries from 17 countries.Some information is also obtained through contact with investigators, sponsors, and funders of vaccine trials. This spreadsheet pairs with the RSV Vaccine and mAb Snapshot, which provides a summary of the RSV vaccine and mAb candidates in development worldwide.To share any updates or corrections to the tracker, please contact rsvsnapshot@path.org.

PATH’s Living Labs Initiative uses human-centered design (HCD) to co-create sustainable health solutions in partnership with the intended users. Organizations that are interested in deeply engaging with health workers, communities, and other public health stakeholders to design and test innovations that increase health system capacity and advance health equity will find information below on how to partner with Living Labs to accelerate and creatively address their priorities. We offer a range of service models and partnerships, and this playbook outlines those options.

The World Health Organization recommends two malaria vaccines—RTS,S and R21/Matrix M™—to protect children as part of a broader malaria control toolkit. These tools are saving lives where introduced in Africa; however, their vaccination schedule comprises four doses and includes new childhood vaccine visits outside of the regular childhood vaccine schedule—adding cost, delivery, and coverage challenges. Also, malaria vaccines are currently recommended for children five months of age and older, meaning that younger infants at risk of malaria remain without vaccine protection.Alternative infant schedules for malaria and other routine vaccines may prevent more disease, ease delivery challenges to achieve coverage targets, and enhance health monitoring for infants—but these potential benefits have not yet been sufficiently studied.This fact sheet describes a PATH-sponsored clinical study in Burkina Faso that is designed to identify an alternative schedule starting in early infancy that can align malaria and other routine vaccinations and maximize disease protection—potentially saving more lives in the future. The malaria vaccine used in the study is R21/Matrix M. The sites conducting the study in Burkina Faso are Groupe de Recherche Action en Santé (GRAS) in Banfora and Institut de Recherche en Science de la Santé (IRSS) in Houndé.